JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...

Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company’s quarterly revenue was up 126.5% compared to the same quarter last year.

It's been a good week for Blueprint Medicines Corporation (NASDAQ:BPMC) shareholders, because the company has just released its latest third-quarter results, and the shares gained 10.0% to US$90.70.

On Friday, Blueprint Medicines Corp (BPMC) stock saw a modest uptick, ending the day at $90.7 which represents a slight increase of $3.19 or 3.65% from the prior close of $87.51. The stock opened at ...

Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Peter ...

Blueprint Medicines (NASDAQ:BPMC) Corporation (NASDAQ:BPMC) has emerged as a prominent player in the biotechnology sector, focusing on developing transformative medicines for patients with ...

Blueprint Medicines (NASDAQ:BPMC) Corporation (NASDAQ:BPMC) has emerged as a prominent player in the biotechnology sector, focusing on developing transformative medicines for patients with genomically ...

This page features the latest news about the Blueprint Medicines Corp stock. Blueprint's BLU-285 shows positive effect in early-stage GIST study; Phase 3 study on tap in H1 2018 Updated results ...

Revenue: US$128.2m (up 127% from 3Q 2023). Net loss: US$56.3m (loss narrowed by 58% from 3Q 2023). US$0.89 loss per share (improved from US$2.20 loss in 3Q 2023). Revenue was in line with analyst ...